Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

393 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 6 of 9

  1. SPD489

    Takeda

    ADHD

    phase 3 small molecule terminated

    1 trial

  2. SPD489

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  3. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  4. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials

  5. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  6. SPD489 40mg

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  7. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  8. SPD489-335

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  9. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  10. SPD503 (Guanfacine hydrochloride)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  11. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  12. SPD503-318

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  13. SPD503-AM

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  14. SYR-322-MET

    Takeda

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  15. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  16. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  17. Soticlestat

    Takeda

    Dravet Syndrome (DS)

    phase 3 small molecule terminated

    3 trials

  18. Spironolactone

    Takeda

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  19. TAK-003

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  20. TAK-019

    Takeda

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  21. TAK-079-3001

    Takeda

    IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)

    phase 3 small molecule active

    1 trial

  22. TAK-279

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    3 trials

  23. TAK-279

    Takeda

    Generalized Pustular Psoriasis

    phase 3 small molecule active

    1 trial

  24. TAK-279-3001

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  25. TAK-279-3002

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  26. TAK-279-PsA-3001

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  27. TAK-279-PsA-3002

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  28. TAK-279-PsA-3003

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  29. TAK-279-PsO-3004

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  30. TAK-330

    Takeda

    Coagulation Disorder

    phase 3 small molecule active

    1 trial

  31. TAK-339-3001

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  32. TAK-438

    Takeda

    Duodenal Ulcer

    phase 3 small molecule completed

    2 trials

  33. TAK-438

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  34. TAK-438

    Takeda

    H. Pylori Infection

    phase 3 small molecule completed

    1 trial

  35. TAK-438

    Takeda

    Gastric Ulcers

    phase 3 small molecule completed

    4 trials

  36. TAK-438

    Takeda

    Gastric Ulcer

    phase 3 small molecule completed

    4 trials

  37. TAK-438

    Takeda

    Erosive Esophagitis

    phase 3 small molecule completed

    4 trials

  38. TAK-536

    Takeda

    Hypertension

    phase 3 small molecule completed

    1 trial

  39. TAK-536CCB

    Takeda

    Grade I or II Essential Hypertension

    phase 3 small molecule completed

    1 trial

  40. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  41. TAK-559

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  42. TAK-559 and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  43. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  44. TAK-559 and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  45. TAK-577-3001

    Takeda

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  46. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  47. TAK-620-2004

    Takeda

    Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)

    phase 3 small molecule active

    1 trial

  48. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.